|  |  |  |  |
| --- | --- | --- | --- |
|  | MEDICAL PRODUCT ALERT | **DRAP ALERT NO.** No II/S/07-22-17 |  |
|  |  | |  |
|  | SUBSTANDARD MOLIMAX ORAL SUSPENSION  (MANUFACTURED BY M/S. ALLIANCE PHARMACEUTICALS PVT LTD, PESHAWAR)  Date: 06th July 2022.  Target Audience:   * Healthcare Professionals- Physicians, Pharmacists, and Nurses. * General Public   Alert Summary:  CDL Karachi has declared the Batch No. L2165 of product “Molimax Oral Suspension” as substandard drug product. Details of the product are given as under:   |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | | **Name of Product** | **Batch no.** | **Mfg. Date** | **Exp. Date** | **Manufactured by** | **CDL Remarks** | | Molimax Oral Suspension | L2165 | 01/022 | 12/023 | M/s. Alliance Pharmaceuticals (Pvt) Ltd., Peshawar. | Assay  Does not comply. |   Action to be taken/ Advice for Healthcare Professionals and general public: -  DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this **substandard product** batch and return the above-mentioned batch to the manufacturer.  If anyone is in possession of the above stated product batch, please do not use. If anyone has used this **substandard product** batch, or if anyone suffer an adverse reaction/event having used this product batch, it is advised to seek immediate medical advice from a qualified healthcare professional, and to report the incident to Drug Regulatory Authority of Pakistan/National Pharmacovigilance Centre.  All medical products must be obtained from licensed, authentic and reliable sources. Their authenticity and condition should be carefully checked. Seek advice from a healthcare professional in case of any doubt. | |  |